Regeneron’s new biologic boosts small molecule binding

Regeneron’s biologic with deep binding pocket beats conventional antibodies at trapping small molecules

Regeneron has expanded its suite of drug discovery technologies by developing a new type of biologic capable of binding small molecules better than conventional antibodies.

The company has been seeking new technologies -- such as nucleic acid therapies and cell therapies --

Read the full 418 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers